Onco-Innovations Income Statement

Financials in millions CAD. Fiscal year is May - April.

Millions CAD. Fiscal year is May - Apr.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jan '26 Jan 31, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023
Revenue	0.15	0.07	-	-
Gross Profit	0.15	0.07	-	-
Selling, General & Admin	1.7	1.32	0.39	0
Research & Development	1.07	0.24	-	-
Operating Expenses	7.73	3.14	0.39	0
Operating Income	-7.57	-3.07	-0.39	-0
Currency Exchange Gain (Loss)	-0.01	-0.01	-	-
Other Non Operating Income (Expenses)	-3.69	-1.63	-	-
EBT Excluding Unusual Items	-11.26	-4.71	-0.39	-0
Impairment of Goodwill	-3.66	-3.66	-	-
Other Unusual Items	0	-0.13	-	-
Pretax Income	-14.92	-8.49	-0.39	-0
Net Income	-14.92	-8.49	-0.39	-0
Net Income to Common	-14.92	-8.49	-0.39	-0
Shares Outstanding (Basic)	47	35	3	-
Shares Outstanding (Diluted)	47	35	3	-
Shares Change (YoY)	9693.55%	905.82%	-	-
EPS (Basic)	-0.32	-0.24	-0.11	-
EPS (Diluted)	-0.32	-0.24	-0.11	-
Gross Margin	100.00%	100.00%	-	-
Operating Margin	-4894.84%	-4702.26%	-	-
Profit Margin	-9648.18%	-13010.36%	-	-
EBIT	-7.57	-3.07	-0.39	-0

Source: S&P Global Market Intelligence. Standard template. Financial Sources.